Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study
The liver was the most common site of progression on first-line ICIs monotherapy. Anti-angiogenesis-based therapy might be an optimal regimen at the time of progression. Patients with isolated oligoprogressive could still benefit from immunotherapy after local treatment.
Authors
- Chong‐Rui Xu (ORCID: https://orcid.org/0000-0002-3474-2809)
- Zhihong Chen (ORCID: https://orcid.org/0000-0002-9749-2501)
- Mingyi Yang (ORCID: https://orcid.org/0000-0001-7677-6292)
- Qing Zhou (ORCID: https://orcid.org/0000-0002-0922-9915)
- Jia‐Yi Deng
- Xiaorong Yang (ORCID: https://orcid.org/0009-0004-1275-304X)
Institutions
- Guangdong Academy of Medical Sciences (CN)
- South China University of Technology (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12885-024-12888-1
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- National Natural Science Foundation of China
- Southern Medical University